

DAFADROS

Drospirenone 3 mg and Ethinylestradiol 0.03 mg

DAFADROS-LS

Drospirenone 3 mg and Ethinylestradiol 0.02 mg



Blossom into

New You



DAFADROS

Drospirenone 3 mg and Ethinylestradiol 0.03 mg

DAFADROS-LS

Drospirenone 3 mg and Ethinylestradiol 0.02 mg

ACNE : IMPROVEMENT IN ACNE (SEVERITY & LESION COUNT)

- Randomized multicentre study¹
- 2069 women over 13 treatment cycle
- **Acne Reduction from 21.5% To 7.8%**



- Multicentre double blind study²
- 538 women evaluated after six cycles
- Improvement in acne severity & lesion

WEIGHT GAIN

- COC ————— common complaint is weight gain³
- Comparative studies demonstrating lower body weight with the drospirenone containing OC than a formulation containing desogestrel



*COC-Combined Oral Contraceptive

HIRSUTISM : IMPROVEMENT IN HIRSUTISM

- Open prospective study⁴
- 20 women
- Significant improvement after six cycles of a drospirenone containing OC.




- Prospective open controlled clinical trial
- 50 women that showed significant improvement at both 6 and 12 months
- Reduction of 67% in the score at 6 months and 78% at 12 months.

ORAL CONTRACEPTIVE (OC)

CONTRACEPTIVE EFFICACY WITH TOLERABILITY AND PATIENT SATISFACTION⁵

- 99% contraception protection rate as compared to other low dose combined oral contraceptive pills
- Discontinued due to adverse events
- Patient satisfaction with drospirenone



PREMENSTRUAL DYSPHORIC DISORDER (PMDD)

- PMDD/PMS— Adversely affects quality of life for a subset of menstruating women⁶
- Randomized placebo-controlled double-blind study


*PMS-Premenstrual Symptoms

OC CONTAINING DROSPIRENONE



ENSURES MENSTRUAL REGULARITIES

COMPARISON OF DROSPIRENONE & DESOGESTREL GROUPS



Improvement In Bleeding Profile Of Women Using The New Drospirenone Oral Contraceptive⁷

Reference:

1. Eur J Contracept Reprod Health Care. 2000;5(1):25-34.
2. Obstet Gynecol. 2008;112(4):773-781.
3. Eur J Contracept Reprod Health Care. 2000;5(2):124-134.
4. Fertil Steril. 2006;85(2):436-440.
5. Contraception. 2004;70(3):191-198.
6. International Journal of Women's Health 5th Aug 2009
7. PLoS One. 2020; 15(6): e0231856.

DAFADROS

Drospirenone 3 mg and Ethinylestradiol 0.03 mg

DAFADROS-LS

Drospirenone 3 mg and Ethinylestradiol 0.02 mg


BACKGROUND:

Drospirenone is 4th generation synthetic progestational compound. Drospirenone is an analog of the diuretic spironolactone, which exerts anti-mineralocorticoid activity. Ethinyl estradiol is a synthetic estrogenic compound.

MECHANISM:

- ✓ Drospirenone and ethinyl estradiol in combination suppress the release of follicle stimulating hormone (FSH) and Luteinizing hormone (LH), preventing ovulation. Combination oral contraceptives (COCs) act by suppression of gonadotropins.
- ✓ Other changes induced by this drug which may aid in the prevention of pregnancy include alterations in cervical mucus consistency, hindering sperm movement, and lowering the chance of embryo implantation.

INDICATION:



DOSAGE:

As directed by the Physician / Gynaecologist.

PRESENTATION:

DAFADROS 21 TABLETS

DAFADROS-LS 24 TABLETS

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-6616-8998, 2693-6656
E-mail: info@larenon.com | Web: www.larenon.com

I am: _____
Call me on: _____
Mail me at: _____

©2021 All rights reserved, La Renon Healthcare Private Limited